Neddylation inhibition sensitises renal medullary carcinoma tumours to platinum chemotherapy.
Daniel D ShapiroNiki Zacharias MillwardDurga N TripathiMenuka KarkiJean-Philippe BertocchioMelinda SoeungRong HeMary E WestermanJianjun GaoPriya RaoTruong N A LamEric JonaschLuigi PerelliEmily H ChengAlessandro CarugoTimothy P HeffernanCheryl L WalkerGiannicola GenoveseNizar M TannirJose A KaramPavlos MsaouelPublished in: Clinical and translational medicine (2023)
Our results suggest that pevonedistat synergises with carboplatin to inhibit RMC cell and tumour growth through inhibition of DNA damage repair. These findings support the development of a clinical trial combining pevonedistat with platinum-based chemotherapy for RMC.